Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

sNDA Withdrawn for Fruquitinib Plus Paclitaxel in Second-Line Gastric Cancer in China

August 30th 2024

The supplemental new drug application for fruquintinib plus paclitaxel in second-line gastric cancer in China has been voluntarily withdrawn.

NuTide:323 Study of NUC-3373 Regimen in Second-Line CRC is Discontinued

August 30th 2024

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.

Early Data Show High Responses With Zanubrutinib Plus Venetoclax in Treatment-Naive Del17p/TP53+ CLL/SLL

August 30th 2024

Alessandra Tedeschi, MD, discusses preliminary data from arm D of the SEQUOIA trial evaluating zanubrutinib plus venetoclax in high-risk, untreated CLL/SLL.

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 29th 2024

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast Cancer

August 29th 2024

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL

August 29th 2024

Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.

RELATIVITY-048 Data Highlight Potential of Triplet ICI Regimen for Advanced Melanoma

August 29th 2024

Ankit Mangla, MD, expands on early data from the RELATIVITY-048 trial evaluating a triplet immunotherapy regimen in untreated advanced melanoma

Dual Checkpoint Blockade Usurps PD-1 Monotherapy as Gold Standard in Unresectable Melanoma

August 28th 2024

Ankit Mangla, MD, expands on key survival data from the phase 2/3 RELATIVITY-047 trial in previously untreated, unresectable, or metastatic melanoma.

BRIA-ABC Trial Explores Novel Post-ADC Strategy for Metastatic Breast Cancer

August 27th 2024

Saranya Chumsri, MD, and Adam M. Brufsky, MD, PhD, discuss the evaluation of Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer

Crovalimab Earns Approval in Europe for Paroxysmal Nocturnal Hemoglobinuria

August 27th 2024

The European Commission has approved crovalimab for adult and pediatric patients with paroxysmal nocturnal hemoglobinuria.

Amivantamab Plus Chemotherapy Wins EU Approval for Pretreated EGFR+ Advanced NSCLC

August 27th 2024

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

Dr El-Jawahri on the Effects of Sexual Health Interventions in HSCT Recipients

August 26th 2024

Areej El-Jawahri, MD, discusses a trial investigating a multimodal intervention to enhance sexual function in patients who have previously received HSCT.

Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC

August 26th 2024

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Dr Saad on the Potential Predictive Value of IL7 SNPs in RCC

August 26th 2024

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

DESTINY-Breast06 Redefines Treatment Paradigms, Calls Necessity of HER2 Testing for T-DXd into Question in HR+ Breast Cancer

August 26th 2024

Jason A. Mouabbi, MD, discusses shifting standards for HER2 testing for T-DXd administration and areas of ongoing ADC development within breast cancer.

DREAMM-7 and DREAMM-8 Data Support Belantamab Mafodotin–Based Combos in R/R Myeloma

August 24th 2024

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

August 23rd 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.

Dr Waks on Ongoing Research in Residual HER2+ Breast Cancer

August 23rd 2024

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

Weighing the Options: Considerations for Adjuvant CDK4/6 Inhibitor Selection in HR+ Breast Cancer

August 23rd 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBC

August 22nd 2024

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.